// App-Quantinova.ai

S153 : OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON)

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Elza Lomaia

  • Beatriz Moiraghi

  • Maria Undurraga Sutton

  • Carolina Pavlovsky

  • Charles Chuah

  • Tomasz Sacha

  • Jeffrey Howard Lipton

  • James K. McCloskey

  • Andreas Hochhaus

  • Philippe H. Rousselot

  • Gianantonio Rosti

  • Hugues De Lavallade

  • Michael J. Mauro

  • Tracey Hall

  • Vickie Lu

  • Shouryadeep Srivastava

  • Michael W. Deininger

Medical Centers

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Universitatsklinikum Jena, Jena, Germany

  • Georgia Cancer Center,Augusta,Verenigde Staten

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

  • Fundaleu, Buenos Aires, Argentina

  • Department of Hematology, Jagiellonian University Hospital, Krakow, Poland

  • Centre for Haematology, Imperial College London, South Kensington Campus,London,United Kingdom

  • Hospital del Salvador, Santiago, Chile

  • Service dHematologie et Oncologie, Hopital de Versailles, Universite Versailles Saint Quentin en Yvelines, Le Chesnay, France

  • The John Theurer Cancer Center at Hackensack Meridian Health,Hackensack,United States

  • University of Utah Health Care,Salt Lake City,United States

  • Almazov National Medical Research Centre of Ministry of Health of Russian Federation,Saint Petersburg,Russian Federation

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Univ of Toronto, Toronto, Canada

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina

  • Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, Singapore

Locations

  • United States

  • Germany

  • Italy

  • Argentina

  • Poland

  • United Kingdom

  • Chile

  • France

  • Russia

  • Canada

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Paraoxonase 1

Drug/Treatment

  • Ponatinib

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • II

Study Id's

  • NCT01207440

  • NCT02467270

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved